Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced the receipt of an Investigational New Drug (IND) authorization letter from India's Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients. The trial's objective is to provide guidance for a 408 patient Phase III trial.
馬薩諸塞州波士頓，2022年12月8日(Global Newswire)--BIOXYTRAN，Inc.開發治療新冠肺炎和其他病毒性疾病的口服和靜脈藥物的臨床階段生物技術公司比亞迪(BIXT)宣佈，已收到印度中央藥物標準控制組織(CDSCO)的研究新藥授權書，以優化新冠肺炎患者的用藥劑量。該試驗的目的是為408名患者的III期試驗提供指導。
About Bioxytran, Inc.
關於雙氧雜環丙烷公司
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at
Bioxtran，Inc.是一家臨床階段的生物技術公司，開發新的療法，旨在治療病毒學、退行性疾病和缺氧方面尚未得到滿足的重大醫療需求。主要候選藥物ProLectin-M是一種新型抗病毒藥物，旨在對抗與炎症、纖維化和惡性疾病有關的Galectins。Bioxtran的其他開發專案是肺纖維化和中風治療。欲瞭解更多資訊，請訪問
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
投資者關係
邁克爾·謝赫
509-991-0245
郵箱：mike.sheikh@bioxtraninc.com
Forward-Looking Statements
前瞻性陳述
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
本新聞稿包括聯盟法律規定的前瞻性陳述，包括本新聞稿中描述的與技術性能有關的陳述。這些前瞻性表述通常由“相信”、“預期”、“預期”、“估計”、“打算”、“計劃”以及類似的表述來識別，儘管並不是所有前瞻性表述都包含這些可識別的詞語。此類陳述會受到重大風險、假設和不確定性的影響。已知的可能導致Bioxtran的實際結果與這些前瞻性陳述預期的結果大不相同的重大因素在前瞻性陳述中描述，風險因素在公司截至2021年12月31日的財政年度的Form 10-K年度報告中描述，這些風險因素在提交給美國證券交易委員會的其他檔案中不時列出。除聯盟證券法要求的範圍外，Bioxtran沒有義務糾正或更新任何前瞻性陳述，無論是由於新資訊、未來事件或其他原因。
譯文內容由第三人軟體翻譯。